NeoTrio: Neoadjuvant Pembrolizumab Alone, Combined With, or in Sequence With Dabrafenib and Trametinib in Resectable BRAF^V600-Mutant Stage III Melanoma

Concurrent neoadjuvant dabrafenib and trametinib and pembrolizumab resulted in high pathologic response rate in patients with stage III melanoma, although with increased toxicity compared with sequential regimen or pembrolizumab monotherapy.